A Cambridge, UK biotech developing bispecific T cell engagers built on fully human T cell receptors to reach intracellular targets in solid tumors and autoimmune disease, which raised a $133 million Series B in November 2026 to take two programs into the clinic.
A Cambridge, UK biotech developing bispecific T cell engagers built on fully human T cell receptors to reach intracellular targets in solid tumors and autoimmune disease, which raised a $133 million Series B in November 2026 to take two programs into the clinic.